HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Ascentage Pharma - The US Stock Listing Will Stimulate Future Growth Potential

China Healthcare Weekly (Jan.5)-TCM VBP Update, Medical Device VBP Result Is Out, WuXi Bio's Outlook

Pre-IPO Xunfei Healthcare Technology (PHIP Updates) - Profitability Are Always the Pain Points

China Healthcare Weekly (Dec.29) - Haier Biomedical Plans to Merge with and Absorb Shanghai RAAS

Equity Capital Markets

Mabwell (Shanghai) Bioscience / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mabwell-shanghai-bioscience-co-ltd" target="_blank" data-smartkarma-citation="entities:44225:1" rel="noopener">Mabwell (Shanghai) Bioscience (MAB HK)</a> has three commercialized products on the market, but their commercialization performance have been far lower-than-expected, leading to small revenue scale and continuously expanding losses. </li>
<li>Mabwell’s ADC technology is actually outdated. We’re not optimistic about the final efficacy of 9MW2821, which is hard to become a Best-In-Class. Other pipeline candidates need to face fierce competition.</li>
<li>Mabwell’s pipeline actually lack competitiveness in the market. Due to weak liquidity, share price of Mabwell in HK market would be traded at a discount to A shares.</li>
</ul>



Mabwell (Shanghai) Bioscience (MAB HK) has three commercialized products on the market, but their commercialization performance have been far lower-than-expected, leading to small revenue scale and continuously expanding losses. 
Mabwell’s ADC technology is actually outdated. We’re not optimistic about the final efficacy of 9MW2821, which is hard to become a Best-In-Class. Other pipeline candidates need to face fierce competition.
Mabwell’s pipeline actually lack competitiveness in the market. Due to weak liquidity, share price of Mabwell in HK market would be traded at a discount to A shares.


Pre-IPO Mabwell (Shanghai) Bioscience - The ADC Technology Is Outdated